A multicentric real-world observational study to describe the use and efficacy of follitropin delta for IVF/ICSI procedures in patients at risk of hypo-response
The results describe the real-world use of follitropin delta and demonstrate its suitability for POSEIDON group 3 and 4 patients. These data complement clinical trial outcomes, supporting clinician decision-making and improving IVF/ICSI outcomes.
Authors
- Géraldine Porcu‐Buisson (ORCID: https://orcid.org/0000-0002-2861-6793)
- Réjean C Lefebvre
- Mathilde Bernot
- Anne-Claire Deloire
Institutions
- Roosevelt Hospital (GT)
- Ferring Pharmaceuticals (France) (FR)
- Institut de Médecine de la Reproduction (FR)
Publication Details
- Journal
- Frontiers in Reproductive Health
- Published
- 2025-09-10
- DOI
- https://doi.org/10.3389/frph.2025.1650946
- Primary Topic
- Reproductive Health and Technologies
- Type
- article
- Field-Weighted Citation Impact
- 0.00